Cargando…

Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents

Severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2), a β-coronavirus, is the cause of the recently emerged pandemic and worldwide outbreak of respiratory disease. Researchers exchange information on COVID-19 to enable collaborative searches. Although there is as yet no effective ant...

Descripción completa

Detalles Bibliográficos
Autor principal: Kim, Cheorl-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194829/
https://www.ncbi.nlm.nih.gov/pubmed/34122058
http://dx.doi.org/10.3389/fphar.2021.590509
_version_ 1783706445632503808
author Kim, Cheorl-Ho
author_facet Kim, Cheorl-Ho
author_sort Kim, Cheorl-Ho
collection PubMed
description Severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2), a β-coronavirus, is the cause of the recently emerged pandemic and worldwide outbreak of respiratory disease. Researchers exchange information on COVID-19 to enable collaborative searches. Although there is as yet no effective antiviral agent, like tamiflu against influenza, to block SARS-CoV-2 infection to its host cells, various candidates to mitigate or treat the disease are currently being investigated. Several drugs are being screened for the ability to block virus entry on cell surfaces and/or block intracellular replication in host cells. Vaccine development is being pursued, invoking a better elucidation of the life cycle of the virus. SARS-CoV-2 recognizes O-acetylated neuraminic acids and also several membrane proteins, such as ACE2, as the result of evolutionary switches of O-Ac SA recognition specificities. To provide information related to the current development of possible anti–SARS-COV-2 viral agents, the current review deals with the known inhibitory compounds with low molecular weight. The molecules are mainly derived from natural products of plant sources by screening or chemical synthesis via molecular simulations. Artificial intelligence–based computational simulation for drug designation and large-scale inhibitor screening have recently been performed. Structure–activity relationship of the anti–SARS-CoV-2 natural compounds is discussed.
format Online
Article
Text
id pubmed-8194829
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81948292021-06-12 Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents Kim, Cheorl-Ho Front Pharmacol Pharmacology Severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2), a β-coronavirus, is the cause of the recently emerged pandemic and worldwide outbreak of respiratory disease. Researchers exchange information on COVID-19 to enable collaborative searches. Although there is as yet no effective antiviral agent, like tamiflu against influenza, to block SARS-CoV-2 infection to its host cells, various candidates to mitigate or treat the disease are currently being investigated. Several drugs are being screened for the ability to block virus entry on cell surfaces and/or block intracellular replication in host cells. Vaccine development is being pursued, invoking a better elucidation of the life cycle of the virus. SARS-CoV-2 recognizes O-acetylated neuraminic acids and also several membrane proteins, such as ACE2, as the result of evolutionary switches of O-Ac SA recognition specificities. To provide information related to the current development of possible anti–SARS-COV-2 viral agents, the current review deals with the known inhibitory compounds with low molecular weight. The molecules are mainly derived from natural products of plant sources by screening or chemical synthesis via molecular simulations. Artificial intelligence–based computational simulation for drug designation and large-scale inhibitor screening have recently been performed. Structure–activity relationship of the anti–SARS-CoV-2 natural compounds is discussed. Frontiers Media S.A. 2021-05-27 /pmc/articles/PMC8194829/ /pubmed/34122058 http://dx.doi.org/10.3389/fphar.2021.590509 Text en Copyright © 2021 Kim. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Kim, Cheorl-Ho
Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents
title Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents
title_full Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents
title_fullStr Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents
title_full_unstemmed Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents
title_short Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents
title_sort anti–sars-cov-2 natural products as potentially therapeutic agents
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194829/
https://www.ncbi.nlm.nih.gov/pubmed/34122058
http://dx.doi.org/10.3389/fphar.2021.590509
work_keys_str_mv AT kimcheorlho antisarscov2naturalproductsaspotentiallytherapeuticagents